2-(n-(phthalimidoacetyl)-n-(polyfluoroloweralkyl))aminobenzophenones

ABSTRACT

THIS INVENTION RELATES TO NOVEL CHEMICAL COMPOSITION OF MATTER USEFUL AS INTERMEDIATES IN THE PREPARATION OF 2OXO-1,3-DIHYDRO-2H-1,4-BENZODIAZEPINES, AND THE 4-N-OXIDES THEREOF, HAVING A POLYFLUOROLOWERALKYL RADICAL ATTACHED AT THE 1-POSITION THEREOF AND TO THE METHODS FOR MAKING AND USING SUCH NOVEL CHEMICAL INTERMEDIATES.

US. Cl. 260-326 N United States Patent 3,755,358 Z-[N-(PHTHALIMIDOACETYD-N-(POLYFLUORO- LOWERALKYL)]AMINOBENZOPHENONES John G. Topliss, West Caldwell, N.J.', assignor to Schering Corporation, Bloomfield, NJ. No Drawing. Continuation-impart .of application Ser. No.

811,637, Mar. 28, 1969, now Patent No. 3,641,147, i

Int. Cl. C07d 27/52 V Claims ABSTRACT OF THE DISCLOSURE This invention relates to novel chemical composition of matter useful as intermediates in the preparation of 2- oxo 1,3 dihydro 2H 1,4 benzodiazepines, and the 4-N-oxides thereof having a poly-fluorolo-weralkyl radical attached at the 1-position thereof and to the methods vfor making and using such novel chemical intermediates.

This application is a continuation-in-part of my vcopending application Ser. No. 811,637, filed Mar. 28, 1969 (now US. Pat. 3,641,147) which in turn is acontinuation-in-part of application Ser. No. 703,245, filed Feb. 6,

1968 (now abandoned) which in turn is a continuationin-part of application Ser. No. 650,581, filed July 3,1967, (now US. Pat. No. 3,429,874) which in turn is a continuation-in-part of application Ser. No. 603,737, filed Dec. 22, 1966 (now abandoned) which in turn is a continuation-in-part of application Ser. No. 520,658, filed Jan. 14, 1966 (now abandoned).

I EIELDOF INV EN'I'lON This invention -r'elatesto compositions of matter identifiable in the art of chemistry aspolyfluoroalkylated i benzodiazepines, to the processes and intermediates useful in the preparation thereof, and to the therapeutic use of such benzodiazepines.

SUMMARY OF INVJENIIQN, 1

V l 3 ,7. 1 r i wherein R is polyfluoroloweralkyl; Q is a member selected from the group consisting of (O),

wherein R and R, are loweriallryl and rt s anlinte'ger of from two to four;A is a? member'selected from the 3,755,358 Patented Aug. 28, 1973 group consisting of hydrogen and wherein T is a member selected from the group consisting of phthalimido and carbobenzoxamide; and R and R are members selected from the group consisting of hydrogen and lower alkyl; and X and Y are members selected from the group consisting of hydrogen, halogen, trifluoromethyl, nitro, lower alkyl and lower alkoxy.

The compounds of Formula I are useful in the preparation of polyfluoroalkylated benzodiazepines having significant pharmacological properties; said polyfluoroalkylated benzophenones being depicted by the following structural formulae:

wherein X is a member of the group consisting of hydrogen, halogen, trifluoromethyl, nitro, lower alkyl, and lower alkoxy, R is polyfiuoroloweralkyl, R is a member of the group consisting of hydrogen, lower alkyl, hydroxy, and lower alkanoyloxy, R is a member of the group consisting of hydrogen and lower alkyl with the proviso that when R is hydroxy or lower alkanoyloxy, R is hydrogen, R is a member of the group consistim of phenyl and Y-substituted phenyl wherein Y is as previously defined and R and R are members of the group consisting of hydrogen and lower alkyl.

The invention sought to be patented, in its composition of matter aspects, may be described as intermediates useful for the preparation of ,X-substituted 1R ,2-oxo.- 3R R -5R 1,3 dihydro 2H 1,4 1 benzodiazepines and as X-substituted lR 2-oxo 3 R 5R G -SR Y1 1,3 di hydro 2H 1,4 benzodiazepine 4 '{oxidesfland to acid addition salts of certain members thereof, f wh'erein R is polyfluoroloweralkyl, R is hydrogenflower: alkyl, hydroxy or lower' alkanoyloxy, R5 is hydrogen or lower 1 alkyl'with the proviso that when R is hydroxyor'lower alkanoyloxy, R is hydrogen; Rpis phenyhor Y-sub stituted phenyl wherein Y is as previously defined;--R and R are hydrogen or lower alkyl;'and X is as previouslydefined. In one of its process aspects the instant invention may. be described as'polyfluoroalkylatingeither"a2 oxo 3R R -.5R 1,3 dihydro-ZH-1,4-benzodiazepine or a 2 oxo 3R R 5R 1,3 -'dihydro -2H 1,4- benzodiazepiue-4-oxide. v In another of its process aspects-this 'inventionmay be described as N-polyfluoroalkylating -a 2-aminobenzophenone. and. converting said polyfluoroalkylated.prodnot obtained therefrom to the desired 2-oxo+3R R -5R,- 1,3 dihydro -,2H -1,4 benzodi-azepine 2 ,one and the 4-oxides thereof. I in another of its process aspects, this invention may 0 be described as residing in .the concept of administering a polyfluoroalkylated benzodiazepine tangible embodimammalian central nervous system and by so doing render such tangible embodiments useful as muscle relaxants, sedatives, anticonvulsants and anti-anxiety agents.

In yet another of its process aspects, this invention may be described as residing in the concept of administering a tangible embodiment of this invention (I) to a mammal to elicit an anti-androgenic, analgesic, antiviral effect and an effect upon the central nervous system.

As used herein, the term, lower alkyl refers to both straight and branched-chain hydrocarbon radicals having up to six carbon atoms such as methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, and the like. The term halogen" comprehends all four halogens, preferably chloro and bromo. The term polyfluoroloweralkyl refers to lower alkyl radicals substituted with more than one fiuoro radical and preferably includes such moieties as trifluoromethyl 2,2,2-trifluoroethyl and 2,2,3,3,3-pentafiuoropropyl and the like. Lower alkoxy includes ether radicals wherein the lower alkyl moiety is as defined for lower alkyl above such as for example, methoxy, ethoxy, propoxy and the like. Lower alkanoyloxy? includes those esters containing the acyl radicals of alkanoic acids including such radicals as formyl, acetyl, propionyl, butyryl, valeryl, hexanoyl and the branched-chain isomers thereof.

In general, the N-polyfluoroloweralkyl-Z-oxo-R -1,3- 2H-l,4-benzodiazepines of Formulae II and III may be prepared by polyfiuoroalkylating the appropriate 2-0110- 5R 1,3 dihydro-ZH-1,4-benzodiazepine. Alternatively, they may be prepared by synthesizing the appropriately substituted benzodiazepine from intermediates already bearing the polyfluoroloweralkyl radicals.

When it is desired to prepare the N-polyfluoroalkylated- 2-oxo-5R 1,3 dihydro-ZH-1,4-benzodiazepines from 2- oxo 5R 1,3 dihydro-2H-1,4 benzodiazepines several polyfiuoroalkylation procedures may be utilized. In a preferred instance the benzodiazepine is subjected to alkylation with a sulfonate ester of polyfluoroloweralkanol of the general formula R OSO Z, wherein R is polyfluoroloweralkyl (preferably trifiuoroethyl) and Z is a member of the group consisting of alkyl, aryl, aralkyl and polyhaloloweralkyl. Exemplary of such sulfonate ester are 2,2,2-trifluoroethyl methyl sulfonate, 2,2,2-trifiuoroethyl benzyl sulfonate, 2,2,2-trifluoroethyl trichloromethyl sulfonate and 2,2,3,3,S-pentafluoropropyl methyl sulfonate and the like. In effecting this alkylation reaction, the re actants are generally heated together in an anhydrous solvent system at temperatures up to 100 in the presence of bases such as sodium hydride, sodium amide, sodium methoxide, potassium t-butoxide and the like. Suitable anhydrous solvents useful for this reaction are dimethylformamide, dimethylacetamide, diphenyl ether, diglime, tetralin and the like. Alternatively, the appropriately. substitutedbenzodiazepine starting materials may be alkylated with apolyfluoroalkyl halide such as 2,2,2-t1ifiuoroethyl, halide and 2,2,3,3,B-pentafluoropropyl halide, said halides havingan vatomic weight greater than 19, preferably iodine. The latterpolyfluoroalkylation reaction is effected innon-reactive organic solvents such as dimethylformamide or aromatic hydrocarbons like benzene, toluene or xylene inthe presence of a basic con densing agent according to standard techniques. Exemplaryiof basic. condensing agents are sodium methoxide, sodium hydride, potassium t-butoxide, sodium amide, and the like. The reaction is usually conducted at temperatures in the range .of from about 20 to about 110 C. preferably around 65- C. and for a period of time ranging from 1 to 24 hours, "preferably about 7'hours, followed by the further addition or polyfluoroalkyl halide and further reaction for approximately 16 hours. The polyfluoroalkylated benzodiazepine products are isolated by filtration of the insoluble salts, evaporation of the filtrate, further iso-.

lated by selective solvent extraction techniques, and purified by'chromatographic techniques such as by elution from an alumina adsorption column.

The foregoing reaction may be schematically depicted as follows:

lil'. O R1 fl) 1% I 2 R I Z oso x B1 A zz R4 I R4 wherein X, R R R R and Z are as previously defined.

The benzodiazepine starting compounds IV and their precursors are prepared by methods analogous to those described in the literature such as J. Org. Chem. 27 562d and 3181if. U

The Z-aminobenzophenone precursors are preparable by well described methods, the choice of method being dependent on the position and kindof substituents desired on the aromatic ringsIA most general method utilizing a substituted anthranilic acid (V) is that described in J. Org. Chem. 27, 3181, wherein an anthranilic acid (V) by reaction with acetic anhydride forms a benzoxazinone '(VI) which, upon reaction with the appropriate Grignard reagent, followed by hydrolysis yields thedesired 2-aminobenzophenone. This sequence of reactions may be depicted as follows:

Reaction Scheme A:

, acetic X v anhydride ooon i X N (11:6 X i- @vctmnger X 3/ H v (VII) X and Y being as previously defined. V

'Exemplary 'of another suitable method for preparing 2-aminobenzophenone s, is that which involves thecondensation'of an X-substituted aniline (VIII) with hen,- zoyl chloride (IX)w under Friedel-Crafts reaction condi tions and rigorously hydrolyzing the primary reaction product yielding the desired Z-aminobenzophenone (VII) Reaction scheme B:

(VIII) X and Y beingfas'previously defined. l

A preferred rnethod utilizes the oridat'ive fission of the appropriate Xand Y-substituted 2,3-diphenylindole, such as with: chromium trioxidev according to standard tech. niques, followed by hydrolysis of the so-formed Z-benzamido-X-substituted benzophenone. This sequence of reactions may be schematically depicted as follows:

(VII) X and R being as previously defined.

It is evident that the position para to the amino group (of Formula VII) corresponds to the 7-position in the final product; a substituent meta to the amino group will appear in the 6- or 8-position of the final product While an ortho substituent will appear in the 9-position of the final product. In those instances wherein a mixtureof 6- and 8-position isomers are formed such compounds may easily be separated by the usual and standard e.g. chromatography.

The cyclization of the Z-aminobenzophenones (VII) to give rise to the X-substituted 2-oxo-5R -l,3-dihydro-2H- 1,4-benzodiazepines (IV) is efiected by any number of methods well known in the art. For example, condensation of a Z-aminobenzophenone V11 with a glycine-ethyl ester hydrochloride, preferably in the presence of pyridine solvent and with heat gives rise to the cyclize starting material IV. Reaction sequence is depicted as follows:

Reaction scheme C Xan d R are as previously defined, R and R being hydrogen.

Alternatively, a glycylamidobenzophenone may be prepared and subsequently cyclized by heating in a nonreactive solvent such as pyridine. The glycylamidobenzophesitu under'there action conditions producingthe corre- 1 sponding 1,4-benzodiazepine. If desired, the acylating reagents may bear protecting groups which upon hydrolysis, will be split ofi to form the desired glycylamidobenzophenone. These alternative methods for producing the benzodiazepine (1V) may be depicted as follows, bearing in "12 mind that although the specifiecarbobenzoxy and phthalimido protective groups are shown, it is to be understood that other equivalently functioning protective groups may similarly be used.

techniques,

In each of D-l through D-4, X' and R areas previously defined, R and R are hydrogen. I 5

When it is desired to prepare the polyfiuoroalkylated-2- oxo-5R -L3-dihydro-2H-1,4-benzodiazepines of Formula II from intermediates already bearing the polyfluoroloweralkyl radicals, several routes of synthesis are applicable depending upon the readya vailability of the starting materials. In general, however, the several routes'of synthesis ultimately employ an appropriately Z-substituted 2-(N-polyfluoroloweralkylamino) benzoph'enone which, by acylation andcyclization steps described for Reaction Schemes C and D, form the desired compounds of Formula II. For example, a 2-(2,2,2-trifluoroethylamino)- benzophenone may be acylated with bromoacetyl bromide (XVI) to yield the corresponding 2-[N-(2,2,2-trifluoroethyl)-a- 7 with ammonia yields the corresponding 2-[N-(2,2,2,-trifiuoroethyD-m aminoacetamido] benzophenone, which compound simultaneously undergoes cyclization under the conditions of amination.

The preparation of the key Z-(N-poly fluoroloweralkylamino)-benzophenone intermediates (I) (A=hydrogen) may readily be accomplished by any one of several techniques. Examplary of such techniques is the above-described alkylation with a polyfluoroloweralkyl halide, and alkylation with a sulfonate ester of polyfluoroalkanols of the formula R OSO Z (as previously defined). In etfecting this alkylation the reactants are heated together in an anhydrous solvent system at reflux temperatures in the presence of inorganic bases such as potassium carbonate. Suitable anhydrous solvents are diphenyl ether, diglime, tetralin, and the like. In addition to the foregoing, the appropriate aminobenzophenones may be first tosylated, whereupon the tosyl derivative will be subjected, to polyfluoroalkylation techniques and the resulting product hydrolyzed to form the desired intermediates of Formula 1 (A=hydrogen) Of course, other variations may be applied to prepare the desired polyfiuoroalkylated intermediates but such variations are to be recognized as equivalents of the abovedescribed processes. For convenience, in describing the variations, the term trifiuoroethylation is often used. It is to be understood, however, that the steps described are of general applicability and that the use of the term trifiuoroethyl is exemplary but in no way limiting. For example, instead of tritiuoroethylating a 2-aminobenzophenone it is feasible to apply the various trifluoroethylation techniques to compounds which, once they are trifluoro ethylated are convertible to the desired 2-(2,2,2-trifiuoroethylann'ne)-benzophenoncs. The conversion to the desired intermediates useful in the preparation of the compounds of Formula II may be structurally depicted as follows:

Reaction Scheme E:

v (iiHgCF: (iHzGF; NE: NE NH C=Q' C=Q' :0 it. in in wherein Q is a moiety convertible to the desired carbonyl function such as a ketal or a cyclic ketal, X and R are as previously defined. The conversion of the carbonyl function may be accomplished by techniques well known in the art.

It is, of course, also possible to form the desired 2-(2, 2,2-trifluoroethylamino) benzophenone by conducting a Friedel-Crafts type reaction upon the appropriate X-substituted N-(2,2,2-trifluoroethyl) aniline, said trifluoroethylated aniline being prepared from the appropriate X-substituted aniline by any one of the above described trifluoro ethylation techniques. Alternatively, the N-polyfluoroloweralkylaniline intermediates may be reacted with bromoacetyl bromide to yield the appropriate X-substituted-N(abromo acetyl)-N-polyfiuoroalkyl aniline, which when reacted with an X-substituted benzoyl halide under Friedel- Crafts reaction conditions produces the previously described Z-[N-(polyfluoroloweralkyl)-u-bromoacetamido] benzophenones. Such reactions may be depicted as follows:

Bonezoyl Chloride A101:

R O R I u 2 3 NH N-C-C a (H) 2: Br

wherein X and Y are as previously defined, R and R are hydrogen and R is trifluoroethyl.

By subjecting the polyfluoroalkylated product (II) to the action of a peroxy acid like peracetic acid, compounds of Formula IIIa are prepared. Alternatively, the intermediate, IV, can be N-oxidized and then polyfluoroalkylated as described above.

To prepare tangible embodiments of Formula III wherein R or R is hydroxy or lower alkanoyloxy the N-oxide of Formula IIIa is heated with acetic anhydride. In this reaction, R and R must be hydrogen. The acetate (XX) so obtained is hydrolyzed to the hydroxy compound (XXI) via titration with alkali. This transformation is depicted as follows:

CF: F:

wherein X, R R and R are as previously defined.

The 2-aminobenzophenones (VII) are treated with thiophosgene to give the corresponding 'isothiocyanates (XXII) which is then allowed to react with iodine penta fluoride to give the corresponding bis (N-trifluoromethylamino)sulfide (XXIII). Reaction of XX'III with bromoacetyl bromide or a functional equivalent gives the required intermediates (Id).

The 2-polyfluoroloweralkylamino-benzophenones of Formula I exhibit anti-androgenic effects upon being subjected to standard pharmacological test procedures and as such are useful in anti-androgenic therapy such as the treatment of benign protstatic hypertrophy. Exemplary of the foregoing, when subjected to the anti-androgenic test procedure of Neri etal. in the European Journal of Pharmacology 1 (1967), pages 438444; the abovedescribed tangible embodiments exhibited significant activity in mammals at about 100-200 mg./kg. of body weight per day. A ."The ot-haloacetamide (e.g. 2-polyfluoroloweralkyl-bromoacetamide) and the a-aminoacetamide (e.g. 2-glycyl) derivatives of the foregoing tangible embodiments exhibit CNS activity and are especiallyuseful as muscle relaxants ,when administered at about 50-100 mg./kg. per day to mammalian hosts; the foregoing being demonstrated by the test procedures described by Irwin, S. and Tedeschi et al. in the publications set forth below. Further, the ja-haloacetamide derivatives exhibit anti-writhing activity at about. 50-l00 mg./'kg./ day; said activity being indicative of analgesic properties. Anti-writhing, activity is essentially the ability of a compound to abate the writhing caused by the injection (i.p.) of an-irritant (e.g. aqueous acetic acid) into a test animal. The test is describedin detail in the Hendershot, L. C. et a1. publication set forth below.

The 2 polyfluoroloweralkylamino benzophenones of a this inventionmay be administered in the above-described dosage ranges in, the manner described below for the 1-polyfluoroloweralkyl-2-oxo 1,3 dihydro-2I-I-1,4-benzodiazepine tangible embodiments.

dih'ydro 5 phenyl-l(2,2,2-trifluoroethyl)-2H-1,4-benzodiaZepine-Z-one has a therapeutic ratio of about 13 which indicates that the neurological impairment dose is about 13 times greater than that dose required to produce a tranquilizing effect according to accepted pharmacological testing methods. By way of further advantage, it has been found that test animals do not develop a tolerance to the tangible embodiments on repeated treatment in anticonvulsant evaluation.

The benzodiazepine and the benzophenone tangible embodiments of this invention are preferably administered via the oral route and for such are compounded into pharmaceutical dosage forms such as tablets, capsules, elixirs, solutions and the like. In the compounding, a dosage unit may contain the usual excipients like starches, gums and alcohol bases commonly employed. In addition, the tangible embodiments may be incorporated into a dosage unit together with another active therapeutic agent.

Based upon standard laboratory investigative procedures such as the Antagonism of Pentylene Tetrazole, Everett and Richards, J. Pharm. and Exp. Ther., vol. 81, p; 402 (1944) and Antagonism of Maximal Electro Shock-Induced Seizures in Mice, Synward, E. A. et al., J. Pharm. and Exp. Ther., vol. 1106, p. 319 (1952) for anti-convulsant activity, the Central Nervous System Activity and Acute Toxicity, Irwin, Science 136, p. 123 (1962) for muscle relaxant and sedative-hypnotic activities, and Antagonism of Foot-Shock Induced Fighting in Mice, Tedesch'i, et al., J. Pharm. and Exp. Ther., vol. 125, p. 28 (1959) and Taming Activity in Monkeys, Randall, Diseases of the Nervous System, vol. 21, p. 7 1960) for anti-anxiety activity, for anti-writhing activity, Hendershot, L. C. et al., J. Pharmacol. and Exp. Ther., vol. 125, pp. 237-240 it is found that when the benzodiazepines are used as an anti-anxiety agents the dosage range is about 0.1-5 mg./kg. of body weight per day,

preferably administered orally in divided dosages. When used as anti-convulsants the dosage range is about 2-30 rug/kg. of body weight per day, preferably orally administered in divided doses. When used as muscle relaxants the dosage range is about 01-15 mg./ kg. of body weight per day, preferably orally administered in divided doses. When used as a sedative-hypnotic the dosage range is about 310 mg./kg. of body weight preferably orally administered in a single dose. Particularly desirable therapeutically effective compounds are: 7-chloro-1,3-dihydro- 5-phenyl-1(2,2,2-trifiuoroethyl) 2H 1,4 benzodiazepine-2-0ne; 7-nitro-l,3-dihydro-5-phenyl-l(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-one; and 7-bromo-1,3-div hydro-S-phenyl-l(2,2,2-trifluoroethyl) 2H 1,.4 benzo- I The 1-polyfluoroloWeralkyl-2-oxo-1,3-dihydro-2H-l,4-

benzodiaze pine tangible embodiments of this invention exert an effect on the central nervous system as determined by standard pharmacological evaluation and as suchare useful astranquilizer-or anti-anxiety agents.

In addition the novel compounds exhibit valuable-anticonvulsant and muscle relaxant-properties. In pharmacological testing there has been observedsignificant differentials between a tranquilizing dose andoneawhich causes neurological impairment. The therapeutic ratio diazepine-2-one.

Tablet formulations (I) Formula and method of manufacture for 7-chloro- 1,3-dihydro 5 phenyl-l-(2,2,2-trifiuoroethyl)-2H 1,4-

benzodiazepine-Z-one:

Enteric coated tablets Mg./core 7-chloro+1,3-dihydro 5 phenyl-1-(2,2,.2-trirfluoroethyl): 2H 1,4 benzodiazepine-2- one, micronized 100.0 Citric acid 1.0 Lactose, USP 33.5 Dicalcium phosphate 70.0 Pluronic F-68 30.0 Sodium lauryl sulfate 15.0 Polyvinylpyrrolidone 15.0 Carbowax 1500' 4.5 Carbowax 6000 45.0 3A alcohol, 50 ml./ 1000 cores.

Corn starch 30.0 Dry:

Sodium lauryl sulfate 3.0

Magnesium stearate 3.0

Total weight 350.0

Procedure: The 7-ch1oro-1,S-dihydro-S-phenyl-1-(2,2,2- trifluoroeth'yl) 2H 1,4 benzodiazepine-Z-one is mixed with the citric acid, lactose, dicalcium phosphate, pluronic and sodium lauryl sulfate. The above mixture is screened through a No. 60 screen and granulated with an alcoholic solution consisting of polyvinylpyrrolidone, Carbowax 1500 and 6000. Add additional alcohol, if necessary, to bring powders to a pasty mass. Add corn starch and continue mixing until uniform granules are formed. Pass through a No. 10 screen, tray and dry in oven at 100 C. for 12-14 hours. Reduce dried granulation through a No. 16 screen, add sodium lauryl sulfate and magnesium sulfate, mix and compress into desired shape on a tablet machine.

Pluronic F68 is a US. registered trademark for a non ionic surface-active agent prepared by the addition of ethylene oxide to a polypropylene glycol which has a molecular weight of 1750.

Coating: The above cores are treated with a lacquer and dusted with talc to prevent moisture adsorption. Sub-coat layers are added to round out the core. A sufiicient number of lacquer coats are applied to make the core enteric. Additional sub-coats and smoothing coats are applied to completely round out and smooth the tablet. Color coats are applied until desired shade is obtained. After drying the coated tablets are polished to give the tablets an even gloss.

(II) Capsule formulations:

Formula: Mg./capsule 7-chloro 1,3 dihydro-S-phenyl-l-(2,2,2-trifluoroethyl) 2H 1,4 benzodiazepine-Z- one, micronized 100.00

Citric acid 1.00

Pluronic, F-68 40.00 Sodium lauryl sulfate 20.00 Lactose 238.00 Magnesium stearate 101.00

Procedure: Mix together 7-chloro-1,S-dihydro-S-phenyl- 1 (2,2,2 trifluoroethyl) 2H-1,4-benzodiazepine-2-one, citric acid, Pluronic, sodium lauryl sulfate and lactose. Pass through a No. 80 screen. Add magnesium stearate, mix and encapsulate into the proper size 2 piece gelatin Method of preparation: Dissolve the sodium saccharin, sodium benzoate, standard granulated sugar and sorbitol solution'in approximately 80% of the required amount of water. Disperse the Veegum in approximately'5% of the required amount of water and add the dispersion to the previously prepared syrup. Prepare a slurry of the 7-chloro 1,3 -'dihydro phenyl-l-(2,2,2-trifluoroethyl)-2H- 1,4-benzodiazepine-2-one with approximately of the required amount of water and pass through a suitable colloid mill until free of grittiness. Add the milled active slurry to the batch. Dissolve the menthol and flavor in the alcohol and add the resulting solution to the batch. Add sufiicient purified water to bring the batch to total volume. Agitate until uniform.

12 (IV) Suppository:

Formula:

2 (N aminoacetyl N trifluoroethyl)-5- nitrobenzophenone ..mg./2 mgs 100 Theobroma oil, pharm. grade to made 2 gms.

- to cool.

The following examples are illustrative of the preparation of representations of the tangible embodiments of this invention: 7

EXAMPLE 1 7-chloro-1,3-dihydro-5-phenyl-1-(2,2,2-trifluoroethyl)- 2H-1,4-benzodiazepine-2-one Prepare a solution of sodium methylate by dissolving 3.9 grams of sodium metal in 500 ml. of methanol. Add 39.0 grams of 7-chloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepine-Z-one. Evaporate the reaction mixture to a residue and dissolve the residue in 170 ml. of dimethylformamide. Add 30 grams of 2,2,2-trifiuoroethyl iodide and stir at room temperature for /2 hour, then beat to 6070 C. for an additional 7 hours. Add 19 grams of 2,2,2-trifiuoroethyl iodide and resume the heating and stirring at 60 C. for an additional 16 hours. Filter off the solids and evaporate the filtrate to a residue in vacuo. Triturate the residue with water and extract with ethyl ether. Wash the ethereal extract with water, dry over anhydrous sodium sulfate and evaporate the solvent to a residue. Extract the residue withethyl ether and filter. Concentrate the ethereal extract to a residue. Dissolve the residue in benzene and chromatograph on 300 grams of alumina contained ina glass column 1.5 inches in diameter to give the crude product. Elute with benzene. Crystallize this product from acetone-petroleum ether to obtain the product of this example.

Alternatively, the compound of this example is prepared as follows: Heat 38.6 g. of 2'-benzoyl-'5-chloro-ptoluene-sulfonamide and 5.4 g. of sodium methoxide in 250 ml. of benzene for 1 hr. under reflux. Then add 42 g. of 2,2,2-trifiuoroethyl iodide and reflux the reaction mixture with stirring for 12 hrs. Cool, filter off the solids, evaporate the solvent, dissolve the residue in 100 ml. of concentrated sulfuric acid and heat the solution on the steam bath for 24 min. Cool the solution, pour into 1 l. of Water, make basic with ammonia and extract with chloroform. Wash the chloroform extracts with water, dry over anhydrous sodium sulfate and evaporate the chloroform to give 2-(2,2,2-trifiuoroethyl)amino-S-chlorobemrophenon which is used in the next step.

Dissolve 29.5 grams of 2-(2,2,2-trifiuoroethyl)-amino- S-chlorobenzophenone obtained above and 21.0 grams of glycine ethyl esterhydrochloride in 200 ml. of pyridine. Heat the solution to reflux and maintain the reflux with stirring for 15 hours. During the first 4 hours remove ap proximately 50 ml. of solvent and replace with dry pyridine. Concentrate the solution in vacuo to a residue. Tritu- I rate the residue in water and extract with ether. Filter 011? any remaining solids and separate the solvent layers. Adjust'the pH of the aqueous solution to 8.0-8.5 and reextract with ether. Combine the ethereal extracts and wash them with water and dry them over anhydrous sodium sulfate. Chromatograph as described above.

. As is apparent to one skilled in the art, by replacing the 7-chloro-l,3-dihyclro-5 phenyl-2H 1,4 benzodiazepine- 2-one of Example 1 with other appropriately substituted 1,4-benzodiazepines the production of other 1-(2,2,2-trifluoroethyl) analogs'may be efiected by following substantially the procedure described in Example 1 above.

7-is0propoxy- 1 ,3dihydro-5 -phenyl- 1 2,2, Z-trifiuoroethyl) -2H- 1,4-b enzodiazepine-Z-one 8-iodo-1,3-dihydro-5-phenyl-1-(2,2,2-trifluoroethyl) 2H-1,4benzodiazepine-2-one 9-fluoro-l ,3-dihydro-5 -phenyl- 1 2,2, Z-trifluoroethyl) 2H-1,4-benzodi aze pine-Z- one 7-chloro-1,3-dihydro-5-(Z-fluorophenyl) -l-(2,2,2-trifiuoroethyl)-2H-1,4-benzodiazepine-2-one fi-trifiuoromethyl-1,3-dihydro-5-phenyl-1-(2,2,2-trifluoroethyl) -2I-I-1 ,4-b enzodiazepine-Z-one 7 -nitro- 1,3-dihydro-5 -phenyl- 1 (2,2, 2-trifiuor0e thyl 2H-1,4-benzodiazepine-2-one.

EXAMPLE 2 2H-1,4-benzodiazepine-2-one-4-oxide (A) Dissolve 50.0 grams of 7-chloro-1,3-dihydro-5- phenyl-ZH-l,4-benzodiazepine-2-one in 1250 ml. of acetic acid. Cool the solution slightly and with agitation add 50 ml. of 40% peracetic acid. Maintain this solution at room temperature for 24 hours and precipitate by the addition of liters of water with agitation. Neutralize the suspension with sodium carbonate and filter. Wash the precipitate with water and crystallize 7-chloro-1,3-dihydro 5-phenyl-2H-1,4-benzodiazepine-2-one-4-oxide from alcohol for use in the next step.

(B) Prepare a solution of sodium methylate by dissolving 3.9 g. sodium metal in 500 ml. methanol. Add 39.8 g. of 7-chloro-1,3-dihydro-5-phenyl-2H-1,4benzodiazepine-2-one-4-oxide, with stirring. Evaporate the methanol and dissolve the residue in 170 ml. dimethylformamide. Add grams of 2,2,2-trifluoroethyl iodide and stir at room temperature for /2 hour. Heat the mixture to 60- 70 C. with stirring for 7 hours. Add 19 grams of 2,2,2- trifluoroethyl iodide and heat with stirring at 60-70 C. for a further 16 hours. Filter oif the insolubles and evaporate and filtrate to a residue in vacuo. Triturate the residue with water, extract with ether, wash the ethereal solution with water, dry the solution over anhydrous sodium sulfate and evaporate to a residue. Triturate the residue with ether and filter. Evaporate the ether to a residue, dissolve the residue in benzene and chromatograph on 300 grams of alumina contained in a glass column 1.5 inches in diameter. Elute with benzene to give the product. Crystallize this product from acetone-petroleum ether to give the purified product.

By subjecting the products enumerated after Example 1 (6) 9-iodo-1,3-dihydro-5-phenyl-1-(2,2,2-trifluoroethy1)- 2H-1,4-benzodiazepine-2-one-4-oxide (7) 8-chloro-1,3-dihydro-5-pheny1-1-(2,2,2-trifiuoroethyl)-2H-1,4-henzodiazepine-2-one-4-oxide (8) 8-fiuoro-1,3-dihydro-5-phenyl-1-(2,2,2-trifiuoroethyl)-2H-1,4 benzodiazepine-2-one-4-oxide (9) '6-methyl-1,3-dihydro-5-phenyl-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-one-4-oxide (10) 7-nitro-1,3-dihydro-5-phenyl-1-(2,2,2-trifluoroto essentially the procedure of part A of this example, a

the corresponding 4-oxides are produced.

EXAMPLE 3 3-acetoxy-7-chloro-1,3-dihydro-5-phenyl-l-(2,2,2-trifluoroethyl) -2H-1,4-henzodiazepine-2-one Suspend 10 grams of 7-chloro-1,3-dihydro-5-pheny1-l- (2,2,2 trii'luoroethyl) 2H 1,4-benzodiazepine-2-one-4- oxide in 100 ml. of acetic anhydride. Heat the mixture on the steam bath for 30 minutes with agitation. Cool and collect the product by filtration. crystallize from acetonepetroleum ether obtaining the product of this example.

This procedure being of substantailly general applicability may be used to convert other 1,4-benzodiazepine-4- oxides to their respective 3-lower alkanoyloxy analogs. Exemplary of such 1,4-benzodiazepine-4-oxides are:

ethyl)r2H-1,4benzodiazepine-2-one-4-oxide (11) 6-chloro-1,3-dihydro-5-phenyl-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-one-4-oxide v (12) Q-methoxy-1,3-dihydro-5-phenyl-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-one-4-oxide 13) 7 -chloro- 1,3 dihydro-5 (2-chlorophenyl)-1- (2,2,2-

trifiuoroethyl)-2H-1,4-benzodiazepine-2-one-4-oxide (14 9-nitr0-1,3-dihydro-5-(4-nitrophenyl)-1-(2,2,2-

trifiuoroethyl)42H!1,4-benzodiazepine-2-one-4-oxide 15 8-methyl-1,3-dihydro5- (3-methoxyphenyl) -1- (2,2,2-trifiuoroethyl)-2H-1,4-benzodiazepine-2-one- 4-oxide (16) 7-ethoxy-1,3-dihydro-5-(3-bromophenyl)-1-(2,2,2-

trifluoroethyl)-2H-1,4-benzodiazepine-2-one-4oxide (l7) 6-trifluoromethyl-1,3-dihydro-5-(4-iodophenyl)-1- (2,2, Z-trifiuoroethyl -2H-1,4-benzodiazepine-2-one- 4-oxide r 18) '9-butyl-l ,3-dihydro-5- (2-fluorophenyl) -1- (2,2,2-

trifluoroethyl)-2H-1,4-benzodiazepine-2-one-4-oxide (l9) S-isopropoxy-1,3-dihydro-5-(Z-trifiuoromethylphenyl) -1-(2,2,2-trifiuoroethy1)-2H-1,4-benzodiaze pine-2-one-4-oxide (20) 8-fluoro-1,3-dihydro-5-(El-chlorophenyD-l-(2,2,2- trifluoroethyl)-2H-l,4-benzodiazepineQ-onel-oxide 21 7-bromo-1,'3-dihydro-5- (4-ethoxyphenyl) -1- (2,2,2- trifluoroethyl)2H-1,4-benzodiazepine-2-one-4-oxide (22) 9-m ethoxy-1,3-dihydro-5-(4-nitrophenyl)-1-(2,2,2-

trifiuoroethyl) -2H- 1 ,4-benzodiazepine-2-one-4-oxide (23) 9-ethyl-1,3-dihydro5-(3-iodophenyl)-1-(2,2,2-trifiuoroethyl)-2H-1,4 benzodiazepine-Z-one-4-oxide The foregoing list of compounds of exemplify the start ing materials to be used in the process of Example 3. When such compounds are treated with the requisite lower alaknoic anhydride under the conditions of this Example, 'the following corresponding products are prouced: r

. (11) 3-butanoyloxye6-chloro-1,3-=dihydro-5-pheny1 1f i (2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-one (1 -aqt9 Y-9:m t Q -1,3- y -p eny I (2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-one 13) 3 propionyloxyfl-chloro-l,3-dihydro-5- (2-chloro-' phenyl) -1- (2,2,2-trifluoroethyl) -2H- 1 ,4-benzodiazepine-2-one (14) 3-caproyloxy-9-nitro 1,3-dihydro-5-(4-nitrophenyl) -1- (2,2,2-trifluoroethyl) -2H-, 1,4-benzodiaze pine-2-one (l5) 3-butanoyloxy-8-methyl-1,3-dihydro-5-(3- methoxyphenyl)-1-(2,2,2-trifluoroethyl)-2H-l,4- benzodiazepine-Z-one e (16) 3-acetoxy-7-ethoxy-1,3-dihydro-5-(3-bromophenyl) -1- (2,2,2-trifluoroetthyl) -2H-1,4-benzodiazepine-Z-one 17 3-valeryloxy-6-trifluoromethyl- 1 3-dihydro-5- (4- iodophenyl)-l- (2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-one 18) 3-acetoxy-9-butyl-1,3-dihydro-5- (2-fluorophenyl) 1- (2,2,2-trifiuoroethyl) -2H-1,4-benzodiazepine-2-one (19) 3-propionyloxy-8-isopropoxy-1,3-dihydro-5- (2- trifiuoromethylphenyl) -1- (2,2,2-trifluoroethyl) -2H- 1,4-benzodiazepine-2-one (20) 3-valeryloxy-8-fluoro-1,3-dihydro-5-(3-chlorophenyl)-1 (2,2,2-trifluoroethyl)-2H-l,4-benzodiazepine-2-one (21 3-caproyloxy-7-bromo-1,3-dihydro-5- (4ethoxyphenyl)-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-one (22) 3-propionyloxy-9-methoxy-1,3-dihydro-5-(4- nitrophenyl) -1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-one (23 3-butanoyloxy-9-ethyl-1,3-dihydro-5-(3-iodophenyl) -1- (2,2,2-trifiuoroethyl) -2H-1,4-benzodiazepine-2-one,

respectively.

EXAMPLE 4 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-1-(2,2,2-trifluoroethyl)-2H-1,4-benzodiazepine-2-one Suspend 5.0 grams of the product of Example 3 in 100 ml. of alcohol. Add one equivalent of a 5% sodium hydroxide solution while stirring. Dilute the reaction mixture with water until the product is fully precipitated. Collect the product by filtration, wash with water, air dry and recrystallize from hexane to yield the compound of this example.

EXAMPLE 5 3-propionyloxy-7-chloro-1,3-dihydro-5-phenyl-1-(2,2,2- trifluoroethyl)-2H-1,4-benzodiazepine-2-one Suspend 3.7 grams of 7-chloro-1,3-dihydro-3-hydroxy- S-phenyl-l-(2,2,2-trifluoroethyl)-2H 1,4 benzodiazepine-Z-one in 25 ml. of benzene and add 1 ml. propionyl chloride. Heat the mixture to reflux and maintain for 2 hours. Cool the reaction mixture and dilute with hexane to incipient crystallization. Cool and filter obtaining the product of this example.

EXAMPLE 6 7-chloro-1,3-dihydro-3-methyl-5-phenyl-l-(2,2,2-trifluoroethyl)-2H-1,4benzodiazepine-2-one Dissolve 23.2 grams of 2-amino-5-chloro-benzophenone in 200 ml. of pyridine. Add 22.9 grams alanine ethyl ester hydrochloride and bring the mixture to reflux. Slowly distill from the reaction mixture approximately 40 ml. of solvent. Reflux the mixture for a total of about 15 hours, then cool slightly and concentrate the mixture under reduced pressure to a residue. Add water to the residue and extract with ether. If there are insolubles present, filter the mixture and separate the solvent layers. Adjust the pH of the aqueous layer to 8.0-8.5 and extract with ether. Combine the ether layers, water wash and dry. Filter and concentrate the layers to a crystalline slurry. There is obtained 7-chloro-1,3-dihydro-3-methyl 5 phenyl-ZH- 1,4-benzodiazepine-2-one which is used in the next step.

Prepare a solution of sodium methylate by dissolving 1.0 gram of sodium metal in 125 ml. methanol. Add 9.8 g. of 7-chloro-1,3-dihydro-3-methyl 5 phenyl-2H-1,4- benzodiazepine-Z-one and evaporate the solution to a residue. Dissolve the residue in 45 ml. of dimethylformamide. Add 8 g. of 2,2,2-tri'fiuoroethyl iodide and stir at roomtemperature for /2 hour, then heat to 60 -70 C. for an additional 7 hours. Add 5 g. of 2,2,2-trifluoroethyl iodide and-resume heating and stirring at 60.-70 C. for an additional 16 hours. Filter, off the residue and'proceed as in Example 1, obtaining the compound of ,this'example.

EXAMPLE 7 1,3-dihydro-5-phenyl-1-(2,2,2-trifluoroethyl)-2H-1,4

benzodiazepine-Z-one Prepare a solution of sodium methylate by dissolving 2.4 grams of sodium metal in 400- ml. of methanol. Add

23.6 g. of 1,3-dihydro-5-phenyl-2l-l-l,4 benzodiazepine-2- one and evaporate the reaction mixture to a residue. Dissolve the residue in 150 ml. of dime thylformamide and i add 25.0 g. of 2,2,2-trifluoroethyl iodide to the mixture.

Stir the mixture at room temperature for' /z"hour,' then heat to 60-70 C. for an additional 7 hours. Add 15 g. of 2,2,2-triflu0roethyl iodide a ndresume the heating and stirring at 60-70 C. for an additional 16 hours. Filter otf the solids and evaporate the filtrate to a residue in vacuo. Triturate the residue with water and extract with ethyl ether. Wash the ethereal extract with water, dry over anhydrous sodium sulfate and evaporate the solvent to a residue. Extract the residue with ethyl ether and filter ed the solids. Concentrate the ethereal extract to a residue and dissolve the residue in benzene and chromatograph on 300 g. of alumina as described in previous examples obtaining the compound of this example.

EXAMPLE 8 1,3-dihydro-5-phenyl-l-(2,2,2-trifiuoroethyl)-2H-1,4- benzodiazepine-2-one-4-oxide Dissolve 5 .0 g. of the product of Example 7 in ml. of acetic acid. Cool the solution slightly and add 5.0 ml. of 40% peracetic acid. Maintain this solution at room temperature for 24 hours and precipitate the product by the addition of 1.0 liter of cold water followed by neutralization with sodium carbonate solution. Filter and wash the precipitate with water. Crystallize from alcohol obtaining the N-oxide of this example.

EXAMPLE 9 7-chloro- 1- (2,2,2-trifiuoroethyl) -5-pl1enyl- 1,3 -dihydro- 2H-1,4-benzodiazepine-2-one (A) 2,2,Z-trifiuoroethyltrichloromethyl sulfonate: Mix 120 gms. of trichloromethylsulfonyl chloride and 50 gms. of 2,2,2-trifiuoroethanol in ml. of water. Heat the mixture with stirring to 50 C. and add dropwise 44 gms. of 50% sodium hydroxide solution. Stir the reaction mixture for 2 hours at 40-45 C. Separate the layers and wash the organic layer with dilute ammonium hydroxide solution followed by a water wash. Dry the washed organic layer over anhydrous sodium sulfate and distil to give 2,2,2-trifluoroethyl trichloromethyl sulfonate boiling at 84-86 C./20 mm. and having the following refractive index: N 1.4275.

(B) 2 (2,2,2 trifluoroethylamino) 5 chlorobenzophenone: Mix with stirring 100 gms. of 2-amino-5-chlorobenzophenone and 61 gms. of 2,2,2-trifluoroethyl trichloromethyl sulfonate. Heat the mixture to C. and hold with stirring at the temperature for 5 hours. Cool the reaction mixture to' room temperature and add 2.0

' liters of ethyl ether. Filter to remove the insoluble solid aliquot of 'each fraction to infrared, thin layer chromatography'...and.zmelting point determinations. Combine thev appropriate eluates, evaporate them 'to a residue and crystallizetheiappropriate residue to yield 40.2 gms. of 2 (2,2,2.--..trifluoroethylamino) -t-chlorohenzophenone melting 99-100 C. p

By replacing the 2,2,2-trifiuoroniethy1 sulfonate of this stepwith equivalent quantities of other sulfonate esters of 2,2,2-trifluoroethanol such as,

2,2,2-trifluor'oethyl phenyl sulfonate 2,2,2-trifiuoroethyl tolyl' sulfonate 2,2,2-trifluoroethyl*methyl sulfonate 2,2,2-triflubroethyl tribr'omomethyl sulfonate, 2,2,2-trifluoroethyltrifiuoromethyl sulfonate,

and bysubstantially following the foregoing procedure there is produced. the desired 2-(2,2,2-trifluoroethyl amino)-5-chlorobenzophenone. I

Similarly, byreplacing the Z-amino-S-chlorobenzophenone reactantof this step with equivalent quantities of Z-aminobenzophenone 5-bromo-2-aminohenzophenone S-trifiuoromethyl-Z-aminob enzophenone 5-methyl-Z-aminobenzophenone S-methoxy-Z-aminobenzophenone S-nitro-Z-aminobenzophenone 3-chloro 2-aminobenzophenone 4-chloro-2-aminobenzophenone 4-trifluoromethyl-2-aminobenzophenone 6-chloro-2-aminobenzophenone,

and by reacting said 2-aminobenzophenones with the sulfonate esters of 2,2,2-trifluoroethanol esters enumerated above and by following substantially the foregoing procedure there is produced,

respectively.

(C) 2 [N-(2,2,2-trifluoroethyl)-a-bromoacetamido]- S-chlorobenzophenone: Dissolve 40.0 gmS.'0f the product of step B in 750 ml. of benzene and add 31 gms. of hromoacetyl bromide. Heat the mixture to reflux and hold there for 3 hours. Cool the benzene solution and wash 3 times with water totaling approximately 450 ml. Dry the benzene solution over anhydrous sodium sulfate and evaporate. Crystallize the residue from hexane to yield 52.1 gms. of 2-[N-(2,2,2,-trifiuoroethyl)-a-bromoacetamido]-S-chlorobenzophenone melting at 115117 C.

By replacing the 2 (2,2,2 trifiuoroethylamino)-5- chlorobenzophenone (product of step B) of this example with equivalent quantities of the benzophenones listed after step B above and by following substantially the procedure of this step there is produced,

2-[N-(2,2,2-trifiuoroethyl)-2-bromoacetamido]- benzophenone 2- [N-(2,2,2-trifiuoroethyl)-2-bromoacetamido] -5- bromobenzophenone 2:[N-(2,2,2-trifluoroethyl)-2-bromoacetamido]-5-tri.fiu-

oromethylbenzophenone 2- [N- (2,2,2-trifiuoroethyl) -2-bromoacetamido] -5-'methylbenzophenone 2- [N- (2,2,2-trifluoroethy1)-2-bromoacetamido] -5- methoxybenzo-phenone 2- [N- (2,2,2-trifiuoroethyl) -2-bromoacetamido] -5- nitrobenzophenone 2- [N- (2,2,2, -trifluoroethyl) -2-bromoacetamido] -3-ch1orobenzophenone 1 2-[N-(2,2,2-trifluoroethyl)-2-bromoacetamido]-4-chlorobenzophenone 2- [N- (2,2,2-trifiuoroethyl) -2-hromoacetamido] -4-trifluoromethylbenzophenone 2- [N- (2,2,2-trifluoroethyl) -2-bromoacetamido] -6-chlorobenzophenone,

respectively.

(D) 7 chloro 1 (2,2,2-trifluoroethyl)-5-phenyl- 1,3-dihydro-2H-1,4-benzodiazepine-2 one: Dissolve 52 gms. of the product of step C in 1.0 liter of chloroform and bubble ammonia gas through the solution at room temperature for- 18 hours. Evaporate the chloroform under reduced pressure, wash the residue with water, extract the residue With ether and wash the ethereal solution with water. Dry the solution over anhydrous sodium sulfate and evaporate the solution to residue. Crystallize the residue from an acetone-petroleum ether mixture to yield 30 gms. of 7-chloro-1-(2,2,2-trifluoroethyl)-5- pheneyl 1,3 dihydro 2H 1,4-benzodiazepine-2-one melting 164-166 C.

By replacing the 2 [N-,(2,2,2-trifluoroethyl)-2-bromoacetamido]-5-chlorobenzophenone of this step with equivalent quantities of the benzophenones listed in step C above, and by following substantially the procedure of this step there is produced,

1- (2,2,2-trifluoroethyl) -5-phenyl-1,3-dihydro-2H- 1,4

benzodiazepine-Z-one 7 -bromo- 1- 2, 2, 2-trifiuoroethyl -5 -phenyl- 1 ,3-dihydro- 2H-1,4-benZodiazepine2-one 7-trifluoromethyl- 1 (2,2,2-trifluoroethyl) -5-phenyl- I ,3-

dihydro-2H-1 ,4-benzodiazepine-2-one 7-methyl- 1- 2,2,2-trifiuoroethyl) -5-phenyl- 1 ,3 -dihydro- 2H- 1,4-b enzodiazepine-2-one 7 -methoxy- 1- 2,2,2-trifiuoroethyl )-5 -pheny1-1, 3-dihydro 2H-1,4-benzodiazepine-2-one 7-nitro- 1-(2,2,2-trifluoroethy1)-5 -phenyl-1 ,3 -dihydro- 2H-1,4-benzodiazepine-2one 9-chloro-1(2,2,2-trifluoroethyl) -S-phenyl-1 ,3-dihydro- 2H- 1 ,4-benzodiazepine-2-one 8-chloro- 1- (2,2,2-trifluoroethyl) -5-phenyl- 1,3-dihydro- 2H-1,4-benzodiazepine-2-one 8-trifluoromethyl-1-(2,2,2-trifluoroethyl)#5-pheny1-1, 3-

dihydro-ZH-1,4-benzodiazepine-2-one 2H-1,4-benzodiazepine-2-one, respectively.

EXAMPLE 10 7-chloro-1-(2,2,2-trifluoroethyl)-5-phenyl-1,3-dihydro- 2H-1,4-benzodiazepine-2-one (A) P-chloro-N (2,2,2 trifluoroethyD-aniline: Add dropwise with stirring 286 gms. of 2,2,2-tri-fiuoroethyl trichloromethyl sulfonate to a refluxing solution of 319 gms. of p-chloroaniline in 800 m1. of toluene. Reflux the reaction mixture for 10 hours, cool and filter oif the solid material. Extract the filtrate with dilute hydrochloric acid. Evaporate the toluene and distil the residue under reduced pressure to obtain the p-chloro-N(2,2,2-trifluoroethyl)-aniline boiling at 116-119 C./ 16 mm.

(B) 2-(2,2,2 trifluoroethylamino) 5 chlorobenzophenone: Stir 5 gms. of the product from Step A above with 15.5 gms. of anhydrous aluminum chloride and 8.2 gms. of benzoyl chloride in 40 m1. of carbon disulfide for 3 hours at room temperature. Heat the mixture to reflux and maintain for an additional '3 hours. Add an ice cold solution of dilute hydrochloric acid. Separate the solvent layers and remove the carbon disulfide by distillation to a residue. Dissolve the residue in an aqueous alcoholic hydrochloric acid solution and reflux the solution for 1 hour. Cool the solution and extract with ethylether to remove the desired product. Wash the ethereal extract with water to remove the excess acid and concentrate the extract to a residue. Dissolve the residue in a minimum volume of 2:1 hexanezbenzene and process as in Example 9 Step B to yield the title product of this step melting at 100 C.

(C) 2-[N (2,2,2-trifluoroethyl)-2-bromoacetamido]- S-chlorobenzophenone: Perform the process described in Example 9 step C above on 2- (2,2,2-trifluoroethylamino)- 5-chlorobenzophenone to yield the title product melting at 114-1l7 C.

(D) 7-chloro-1-(2,2,2-trifluoroethyl) 5 phenyl-1,3- dihydro-ZH-1,4-benzodiazepine-2-one; Perform the process of Example 9 step D on the product from step C above to yield the product of this example.

In a similar manner by substituting the benzoyl chloride of part B of this example with o-chlorobenzoyl chloride and by substantially following the procedures of parts B and C of this example, there is produced 2-[N- (2,2,2-trifluoroethyl) 2-bromoacetamido]-2,5-dichloroibenzophenone. Suspend the product in 40 ml. of a 1:1 mixture of ether and 2 N ammonium hydroxide and stir at room temperature until the solids dissolve. Separate the solvent layers and dry the ether layer over anhydrous sodium sulfate. Evaporate the solution to a residue to obtain 2-(N-2,2,Z-trifluoroethyl-N-aminoacetyl) -amino-2',5- dichlorobenzophenone.

EXAMPLE 11 7-chloro-l-(2,2,2-trifluoroethyl)-S-phenyl-l,S-dihydro- 2H-1,4-benzodiazepine-2-one (A) N-(a-bromoacetyl)-p-chloro-N (2,2,2 trifiuoroethyl)-aniline: Reflux a solution of 20 gms. p-chloro-N- (2,2,2-trifiuoroethyl)-aniline as prepared in step A of Example 10 above with 19 gms. of a-bromoacetyl bromide in 400 ml. of benzene. Continue the reflux for 3 hours and cool the mixture to room temperature. Wash the benzene solution with water and dry it over anhydrous sodium sulfate. Evaporate the benzene and crystallize the residue to give the N-(a-bromoacetyl)-p-chloro-N-(2,2,2-trifluoroethyD-aniline.

(B) 5-chloro-2-[N-(2,2,2-trifluoroethyl) 2 bromoacetamido1-benzophenone: Dissolve 11 gms. of the product from step A above in carbon disulfide, add 13 gms. of anhydrous aluminum chloride and 7 gms. of benzoyl chloride and stir at room temperature for 18 hours. Add an ice cold solution of dilute hydrochloric acid and stir the mixture for 10 to 15 minutes. Separate the solvent layers and process as in step C Example 9 above to obtain the title product melting l151 17 C.

(C) 7-chloro-1-(2,2,2-trifluoroethyl) 5 phenyl-1,3- dihydro-ZH-1,4-benzodiazepine-2-one: Dissolve the product of step B above in chloroform and subject the solution to the process of Example 9 step D to obtain the title product whose melting point is 164-l66 C.

EXAMPLE l2 7-chloro-1-(2,2,2-trifluoroethyl)-5-phenyl-1,3-dihydro- 2H-1,4-benzodiazepine-2-one-4-oxide (A) 2 [2 (N-acetoxyacetamido)-N-(2,2,2-trifluoroethyl) -acetamido]-5-ch1orobenzophenone: Dissolve 31.4 gms. of 2 (2,2,2 trifluoroethylamino)-5-chlorobenzophenone and 19.4 gms. of N-acetoxy-N-acetylglycyl chloride in 500 ml. of benzene and heat the solution to reflux. Hold the solution at reflux for 3 hours and remove the benzene under reduced pressure. Crystallize the residue from an acetone-petroleum ether mixture to give the product of this example.

(B) 7-chloro-1-(2,2,2 trifluoroethyl) 5 phenyl-1,3- dihydro 2H-1,4-benzodiazepine-2-one-4-oxide: Dissolve 27 gms. of the product of step A above in ml. of ethyl alcohol. Add 10 ml. of 15% hydrochloric acid and reflux for :15 minutes. Dilute with water and chill the mixture. Collect the solids by filtration. Wash the solids with mother liquor and with Water and dry at 50 C. Crystallize the solids from alcohol to yield the product of this example.

EXAMPLES 13 7-chloro-1-( 2,2,2-trifluoroethyl)-5-phenyl-1,3-dihydro- 2H-1,4-benzodiazepine-2-one Prepare 20 ml. of a saturated solution of hydrogen bromide in acetic acid and cool to room temperature. Add to this solution 2 grams of 2- [2-c-arbobenzoxamido- N-(2,2,2 trifluoroethyb] acetamido 5 chlorobenzophenone and stir the mixture for 1 hour. Concentrate the solution under reduced pressure and below 35 C. to a residue and add ether (20 ml.) to give a pasty suspension. Add 20 ml. of cold dilute (2 N) ammonium hydroxide and mix thoroughly. Separate the solvent layers and dry the ether layer over anhydrous sodium sulfate. Evaporate the solution to a residue to obtain the Z-[N-glycyl-N- (2,2,2-trifluoroethyl)] amino-S-chlorobenzophenone.

(B) 7-chloro l (2,2,2 trifluoroethyl)-5-phenyl-1,3- of the product from step above in 25 ml. of xylene. Reflux the mixture for 3 hours and remove the solvent under pressure to a residue and crystallize the residue :from acetone-petroleum ether to obtain the title compound.

EXAMPLE 14 7-chloro-l-(2,2,2-trifluoroethyl)-5-phenyl-1,3-dihydro- 2H-1,4-benzodiazepine-2-one Dissolve 10 grams of 2-[N-phthalimidoacetyl-N-(2,2,2- trifluoroethyl)]-amino-5-chlorobenzophenone in a mixture of 100 ml. of chloroform and 100 ml. of ethanol. Add a solution of 2.5 grams of hydrazine hydrate in 2.5 ml. of water. Allow the mixture to stand at room temperature for 24 hours and remove the solvents under reduced pressure at or below 35 C. Triturate the residue with a 1:1 mixture of 2 N ammonium hyroxide and ether until the solids have dissolved. Separate the solvent layers and extract the ether layer with a 10% hydrochloric acid solution. Basify the acid extract and back-extract it with ether. Evaporate the ether layer to a residue and crystallize the product to obtain the 7-chlorol-(2,2,2-trifluoroethyl) 5 phenyl 1,3-dihydro-2H-1,4-benzodiazepine-2- one product of this example melting 164-1 65 C.

EXAMPLE 15 7-chloro-1,3-dihydro-5-(2-fluorophenyl)-1-(2,2,2- trifluoroethyl) -2H-1,4-benzodiazepine-2-one Dissolve 10 grams of 2-[N-phthalimidoacetyl-N-(2,2,2- trifiuoroethyl) ]-amino-2'-fluoro-5-chlorobenzophenone in a mixture of 100 ml. of chloroform and 100 ml. of ethanol. Add a solution of 2.5 grams of hydrazine hydrate in 2.5 ml. of water. Allow the mixture to stand at room temperature for 24 hours and remove the solvents under reduced pressure at or below 35 C. Triturate the residue with a 1:1 mixture of 2 N ammonium hydroxide and ether until the solids have dissolved. Separate.

the solvent layers and extract the ether layer with a 10% hydrochloric acid solution. Basify the acid extract and back-extract it with ether. Evaporate the ether layer to a residue and crystallize the product to obtain the product of this example.

I claim: 5

1. A'compound selected from the group of compounds having the structural formula:

wherein R is polyfiuoroloweralkyl; R and R are members selected from the group consisting of hydrogen and lower alkyl; and X and Y are members selected from the group consisting of hydrogen, halogen, trifiuoromethyl, nitro, lower alkyl and lower alkoxy.

2. A compound of claim 1 wherein R is trifluoroethyl, R and R are hydrogen, X is halogen and Y is hydrogen.

3. A compound of claim 1 wherein R is trifluoroethyl, R and R are hydrogen, and X and Y are halogens.

4. The compound of claim 3 wherein X is chloro at position 5, said compound being 2-[N-phtha1imidoacety1- N- (2,2,2-trifluoroethyl) ]amirIo-S-chlorobenzophenone.

5. The compound of claim 4 wherein X is chloro at position 5, and Y is fluoro at position 2', said compound being 2-[N-phthaiimidoacetyl-N (2,2,2 trifiuoroethyD] amino-2-fluoro-S-chlorobenzophenone.

References Cited UNITED STATES PATENTS P0-1050' EPATEN @FFE'EE EERTEE ifiri iifi U5- @QEEEREQTEQN Patent No. 5 3755 x55 fiat-ad 3/28/75 Invmtaria) JOh-Yl GB Tsplizzs It is certificad than: arm: agafiaif in $315: abova idmxtifiead patent and that saifi Letters ?a:ent am ha-rainy mrmcm aa sshmm below:

Column line &3, C25 Ci'lg (301122521 6, line "H n 1 2:; "Q A .W 51 7-H w W 25 Q g anemia read g mm-ma d .LLAQ Cal, R should -r N 1 bread. "R Column 8 line i EH2 she-i116. reaci wfi Column 13- line 7%, "'22" should reaxl Column 16, line #1, "compound of exemplify" should ream". --eomp0um1s exemplify--. Column 19, lines FEB-{2&3 arifluoroethylamino) 5- nitrcbenzophenone 2412,92,2421 iflfierce'ihylamino)-5-nitrobenzophenone" shculd 2-(E,2,2 eriflumaoethylamine)-5,- nitrobenzophenone -n OIL-aim Cslumn 2 line 5, "The compound of claim. 5" should. reacl --Th cnmpound claim 2". Claim 5, Column 2 line 8 The eampnund 0f ala im -1" shcmld read --'I3he compound cf claim 'j -e Signed and sealed lat day {2f Gctabmr 1974.

(SEAL) Attest:

MCCOY M. GFLBSON' JRa (3,. MARSEELLL DANN Attesting Offices: Commi siozze r a; Patents 

